Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases
COVID-19 trials have relied on symptomatic subjects for judging the effectiveness of vaccine candidates, whereas asy–mptomatic subjects have been suspected as the main driver of the pandemic. An assumption of the same impact on symptomatic and asymptomatic breakthrough infections is shown to be flaw...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Online Access: | http://dx.doi.org/10.1080/21645515.2021.1994800 |
| _version_ | 1797673225919922176 |
|---|---|
| author | Richard Paul Junghans |
| author_facet | Richard Paul Junghans |
| author_sort | Richard Paul Junghans |
| collection | DOAJ |
| description | COVID-19 trials have relied on symptomatic subjects for judging the effectiveness of vaccine candidates, whereas asy–mptomatic subjects have been suspected as the main driver of the pandemic. An assumption of the same impact on symptomatic and asymptomatic breakthrough infections is shown to be flawed, resulting in an overestimate of the vaccines’ true effectiveness. Recent available data provide the first large-scale unbiased data on asymptomatic versus symptomatic infections postvaccination, providing a unique opportunity to reassess the true infection rates after vaccination. By this, the breakthrough of the BNT162b2 vaccine is seen to be 12% rather than 5% for a corrected overall efficiency (symptomatic + asymptomatic) of 88% with the original virus strain in a real-world setting. |
| first_indexed | 2024-03-11T21:42:26Z |
| format | Article |
| id | doaj.art-2ce6713232714e16a5bf901ea39e8cbc |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:42:26Z |
| publishDate | 2021-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-2ce6713232714e16a5bf901ea39e8cbc2023-09-26T12:51:26ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-12-0117125133513410.1080/21645515.2021.19948001994800Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic casesRichard Paul Junghans0Boston UniversityCOVID-19 trials have relied on symptomatic subjects for judging the effectiveness of vaccine candidates, whereas asy–mptomatic subjects have been suspected as the main driver of the pandemic. An assumption of the same impact on symptomatic and asymptomatic breakthrough infections is shown to be flawed, resulting in an overestimate of the vaccines’ true effectiveness. Recent available data provide the first large-scale unbiased data on asymptomatic versus symptomatic infections postvaccination, providing a unique opportunity to reassess the true infection rates after vaccination. By this, the breakthrough of the BNT162b2 vaccine is seen to be 12% rather than 5% for a corrected overall efficiency (symptomatic + asymptomatic) of 88% with the original virus strain in a real-world setting.http://dx.doi.org/10.1080/21645515.2021.1994800 |
| spellingShingle | Richard Paul Junghans Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases Human Vaccines & Immunotherapeutics |
| title | Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases |
| title_full | Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases |
| title_fullStr | Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases |
| title_full_unstemmed | Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases |
| title_short | Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases |
| title_sort | technical note the calculated real world bnt162b2 vaccine efficacy was 88 when accounting for asymptomatic cases |
| url | http://dx.doi.org/10.1080/21645515.2021.1994800 |
| work_keys_str_mv | AT richardpauljunghans technicalnotethecalculatedrealworldbnt162b2vaccineefficacywas88whenaccountingforasymptomaticcases |